Summit Therapeutics (SMMT) Return on Equity (2017 - 2025)
Historic Return on Equity for Summit Therapeutics (SMMT) over the last 8 years, with Q3 2025 value amounting to 0.29%.
- Summit Therapeutics' Return on Equity rose 200.0% to 0.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.29%, marking a year-over-year increase of 200.0%. This contributed to the annual value of 1.01% for FY2024, which is 50100.0% up from last year.
- Summit Therapeutics' Return on Equity amounted to 0.29% in Q3 2025, which was up 200.0% from 0.42% recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Return on Equity registered a high of 0.18% during Q3 2022, and its lowest value of 0.93% during Q1 2024.
- Moreover, its 4-year median value for Return on Equity was 0.31% (2024), whereas its average is 0.39%.
- In the last 5 years, Summit Therapeutics' Return on Equity tumbled by -6400bps in 2024 and then skyrocketed by 5900bps in 2025.
- Summit Therapeutics' Return on Equity (Quarter) stood at 0.29% in 2022, then plummeted by -123bps to 0.64% in 2023, then skyrocketed by 52bps to 0.31% in 2024, then grew by 5bps to 0.29% in 2025.
- Its last three reported values are 0.29% in Q3 2025, 0.42% for Q2 2025, and 0.34% during Q1 2025.